LuciAxi — Axitinib 5 mg, 60 pcs, Lucius

LuciAxi — Axitinib Tablets 5 mg, 60 Tablets

Product code: 494

26373₴ 28697₴ -8% On order · from 10 days

Analogues

1
Active ingredient
Dosage form Tablets
Tablets per pack 60

LuciAxi is a potent targeted antineoplastic agent belonging to the selective angiogenesis inhibitor class, indicated for the treatment of renal cell carcinoma. The active pharmaceutical ingredient is axitinib at a strength of 5 mg supplied as film-coated oral tablets (Axitinib Tablets 5 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Axitinib is a potent, oral, selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. Blockade of these receptors inhibits new blood vessel formation required for tumor nourishment and progression (angiogenesis) while inducing regression of existing tumor vasculature. Axitinib is characterized by high selectivity and potency, making it highly effective for treating advanced renal cell carcinoma following failure of prior systemic therapy (such as cytokines or other tyrosine kinase inhibitors).

Supplied in a package containing 60 tablets of 5 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciAxi 5 mg:

  • ✅ High Selectivity & Potency: Powerful inhibition of VEGFR 1, 2, and 3 with minimal off-target kinase activity.
  • ✅ Proven Efficacy: Significant improvement in progression-free survival in advanced renal cell carcinoma.
  • ✅ Convenient Oral Administration: Taken orally twice daily regardless of food intake.
  • ✅ Flexible Dose Titration: Allows dose adjustments based on individual patient tolerability and blood pressure response.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Inlyta).

LuciAxi is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Axitinib — 5 mg.
  • Excipients: Microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate. Coating: hypromellose, titanium dioxide, triacetin, colorants.

Packaging and Presentation: Film-coated tablets, 5 mg strength. Each package contains 60 tablets along with prescribing information. Labeled with LuciAxi (Axitinib Tablets 5 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) types 1, 2, and 3. These receptors play a critical role in pathological angiogenesis, tumor growth, and metastasis. Axitinib potently suppresses VEGFR-2 phosphorylation in vivo and in vitro, resulting in inhibition of tumor vascularization and ischemic tumor cell death.

Pharmacokinetics:

  • Absorption: Rapidly and almost completely absorbed following oral ingestion. Absolute bioavailability averages 58%. Peak plasma concentration (Tmax) is achieved within 2.5 to 4.1 hours.
  • Distribution: Human plasma protein binding exceeds 99% (bound primarily to albumin and alpha-1-acid glycoprotein).
  • Metabolism: Extensively metabolized in the liver via cytochrome P450 enzymes (predominantly CYP3A4/5, with minor contributions from CYP1A2, CYP2C19, and UGT1A1) into inactive metabolites.
  • Elimination: Excreted predominantly via feces (approx. 41% as metabolites) and renally (approx. 23%). Terminal elimination half-life (T1/2) ranges from 2.5 to 6 hours.

LuciAxi is indicated in adult patients for:

  • Renal Cell Carcinoma: Treatment of advanced renal cell carcinoma following failure of prior systemic therapy (prior sunitinib or cytokine therapy).

LuciAxi is administered orally twice daily approximately 12 hours apart.

Dosing Regimen:
The recommended starting dose is 5 mg twice daily. Tablets should be taken regardless of food intake (can be swallowed with water).

Dose Titration: Dosage may be adjusted by the physician (increased up to 7 mg or 10 mg twice daily, or decreased down to 3 mg or 2 mg twice daily) based on individual patient tolerability and blood pressure levels.

Administration of LuciAxi is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to axitinib or any excipient.
  • Severe Hepatic Impairment: Pronounced liver dysfunction (Child-Pugh Class C).
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.

Axitinib is metabolized by hepatic CYP3A4/5 enzymes:

  • Strong CYP3A4 Inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice): Increase axitinib blood concentrations and toxicity risks. Avoid concurrent use.
  • Strong CYP3A4 Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): Decrease axitinib blood concentrations and reduce antitumor efficacy. Avoid concurrent use.
  • Antihypertensive Agents: Blood pressure monitoring is mandatory since axitinib frequently induces arterial hypertension.

Pregnancy:
LuciAxi is contraindicated during pregnancy. Axitinib exhibits proven teratogenic and embryotoxic potential. Females of reproductive potential must utilize effective contraception during treatment and for at least 1 week following the final dose.

Lactation:
Excretion of axitinib into human breast milk is unstudied. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions include:

  • Cardiovascular System: Arterial hypertension (very common adverse reaction requiring continuous blood pressure monitoring and antihypertensive therapy).
  • Gastrointestinal Tract: Diarrhea, nausea, vomiting, decreased appetite, stomatitis, abdominal pain, constipation.
  • General Disorders: Fatigue, asthenia, weight loss, dysphonia (hoarseness).
  • Dermatologic Reactions: Palmar-plantar erythrodysesthesia (hand-foot syndrome), dry skin, rash.
  • Hematologic & Laboratory Toxicity: Elevations in serum creatinine and liver transaminases, anemia, thrombocytopenia.

Symptoms:
Specific acute overdose symptoms of axitinib are unestablished. Anticipated manifestations include hypertension, diarrhea, fatigue, and hemorrhage.

Treatment:
No specific antidote exists. Supportive and symptomatic care, blood pressure monitoring, and vital organ support should be initiated in case of overdose.

Storage Requirements for LuciAxi 5 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Do not use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciAxi 5 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics and Axitinib Tablets 5 mg.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 14.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00